Thelial

Thelial is a biotechnology company focused on developing first-in-class therapies that restore the integrity of the epithelial barrier to treat chronic inflammatory and autoimmune diseases. The company's approach targets the underlying 'leaky' barrier dysfunction common in conditions such as inflammatory bowel disease and certain ophthalmic disorders. By utilizing a proprietary screening platform, Thelial identifies small molecules capable of reinforcing tight junctions and preventing the systemic translocation of pro-inflammatory triggers. Their lead programs are currently in the pre-clinical stage, aiming to provide disease-modifying options where current immunosuppressive treatments fall short.